SCHEMBL10043720

SCHEMBL10043720

CCN1CCN(c2cccc(C(=O)Nc3ccc(C)c(-c4cc5cnc(C)cc5n(C)c4=O)c3)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.47
▸ RAF1 P04049 8/20 0.45
▸ BRAF P15056 8/20 0.45
▸ MAPT P10636 4/20 0.45
▸ TP53 P04637 1/20 0.45
▸ MAPK14 Q16539 2/20 0.44
▸ TNK2 Q07912 1/20 0.44
▸ MAP4K2 Q12851 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ CHRM5 P08912 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KLK7 P49862 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043727 0.90 RAF1 (0.48) SYKRAF1BRAFMAPTTP53
SCHEMBL502521 0.88 BRAF (0.61) SYKRAF1BRAFMAPTTNK2
SCHEMBL10072186 0.83 SYK (0.55) SYKBRAFMAPTTP53MAPK14
SCHEMBL10043699 0.82 SYK (0.57) SYKRAF1BRAFMAPTMAPK14
SCHEMBL10043677 0.82 NPC1 (0.52) SYKRAF1BRAFMAPTTP53
SCHEMBL10072188 0.82 SYK (0.53) SYKBRAFMAPTMAPK14
SCHEMBL10071823 0.81 MAPK14 (0.55) BRAFMAPK14MAP4K2HTT
SCHEMBL10072015 0.81 BRAF (0.53) SYKRAF1BRAFTNK2MAP4K2
SCHEMBL10043663 0.81 SYK (0.51) SYKMAPTTP53MAPK14KMT2A
SCHEMBL10043704 0.81 BRPF1 (0.53) SYKMAPTTP53MAPK14TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885RAF1 11/4885BRAF 36/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885RAF1 11/4885BRAF 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback